Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P220029/S003

Optilume BPH Catheter System

Urotronic, Inc. · Decision date Dec 15, 2025

FDA DECISIONP220029/S003

What did the FDA approve?

FDA records P220029/S003 as a supplement to PMA P220029, with the supplement type “Normal 180 Day Track No User Fee”. The recorded decision is approval, dated Dec 15, 2025.

FDA approval order statement

Approval of the revised protocol for the post-approval study (PAS)
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track No User Fee
Clinical specialty
Gastroenterology, Urology
Decision date
Dec 15, 2025
FDA change category
Postapproval Study Protocol

FDA source record

Regulatory record facts

Identifier
P220029/S003
Regulatory pathway
PMA supplement
Product code
QXB
Decision code
APPR
Decision date
Dec 15, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Drug coated prostatic dilation catheter for benign prostatic hyperplasia.

Product code
QXB
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P220029/S003 received

    Application receipt date recorded by FDA.

  2. P220029/S004 · Related supplement

    Optilume BPH Catheter System

  3. P220029/S003 · FDA decision

    Normal 180 Day Track No User Fee

Timeline entries are records held by MedtechLedger for P220029. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P220029

Product / regulatory recordCompanyPathwayDecision dateSource
Urotronic, Inc.PMA supplementDec 12, 2025FDA

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Urotronic, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
2495 Xenium Ln., Minneapolis, MN, 55449

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records